Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors - PubMed (original) (raw)

Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors

Y Li et al. J Exp Med. 1996.

Abstract

Genetic modification of many types of mouse tumors to express the B7-1 or B7-2 molecules, natural ligands for the T cell-costimulatory molecule CD28, increases their immunogenicity. However, even after transfection with the B7-1 and/or B7-2 genes, poorly immunogenic tumors fail to elicit and efficient immune response. We report here that two such tumors, the Ag104A sarcoma and the K1735-M2 melanoma, become immunogenic after transfection of the genes encoding murine B7-1 together with CD48, which is the natural ligand for CD2. Tumor-specific CD8+ cytotoxic T lymphocytes were readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-type Ag104A sarcoma cells. A similar approach may be useful for developing therapy for other poorly immunogenic tumors, including those in humans.

PubMed Disclaimer

Similar articles

• Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
  Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK. Ostrand-Rosenberg S, et al. Tissue Antigens. 1996 May;47(5):414-21. doi: 10.1111/j.1399-0039.1996.tb02577.x. Tissue Antigens. 1996. PMID: 8795142
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
  Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE. Chen L, et al. J Exp Med. 1994 Feb 1;179(2):523-32. doi: 10.1084/jem.179.2.523. J Exp Med. 1994. PMID: 7507508 Free PMC article.
• Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
  Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G. Martin-Fontecha A, et al. Eur J Immunol. 1996 Aug;26(8):1851-9. doi: 10.1002/eji.1830260828. Eur J Immunol. 1996. PMID: 8765031
• The role of B7 costimulation in T-cell immunity.
  Harris NL, Ronchese F. Harris NL, et al. Immunol Cell Biol. 1999 Aug;77(4):304-11. doi: 10.1046/j.1440-1711.1999.00835.x. Immunol Cell Biol. 1999. PMID: 10457196 Review.

Cited by

• Treatment of lymphoma with adoptively transferred T cells.
  Till BG, Press OW. Till BG, et al. Expert Opin Biol Ther. 2009 Nov;9(11):1407-25. doi: 10.1517/14712590903260785. Expert Opin Biol Ther. 2009. PMID: 19723016 Free PMC article. Review.
• Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword?
  Tarazona R, Casado JG, Soto R, DelaRosa O, Peralbo E, Rioja L, Peña J, Solana R. Tarazona R, et al. Cancer Immunol Immunother. 2004 Oct;53(10):911-24. doi: 10.1007/s00262-004-0507-y. Epub 2004 May 4. Cancer Immunol Immunother. 2004. PMID: 15127235 Free PMC article. Review.
• Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
  Yang S, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Ronai Z, Hellstrom I, Hellstrom KE. Yang S, et al. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4990-5. doi: 10.1073/pnas.0400880101. Epub 2004 Mar 29. Proc Natl Acad Sci U S A. 2004. PMID: 15051893 Free PMC article.
• Preliminary study on the cooperation of IL-6 and mB7-1 in the induction of effective antitumor immunity in vitro.
  Qu S, Liu R, Wang Y, Wang J. Qu S, et al. J Tongji Med Univ. 1999;19(2):86-9. doi: 10.1007/BF02886881. J Tongji Med Univ. 1999. PMID: 12840844
• Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
  Parviz M, Chin CS, Graham LJ, Miller C, Lee C, George K, Bear HD. Parviz M, et al. Cancer Immunol Immunother. 2003 Dec;52(12):739-50. doi: 10.1007/s00262-003-0405-8. Epub 2003 Aug 14. Cancer Immunol Immunother. 2003. PMID: 12827306 Free PMC article.

References

1. 1. Immunol Today. 1993 Oct;14(10):483-6 - PubMed
2. 1. J Exp Med. 1994 Jan 1;179(1):341-6 - PubMed
3. 1. J Immunol. 1994 Apr 1;152(7):3361-9 - PubMed
4. 1. J Immunol. 1994 Jul 1;153(1):421-8 - PubMed
5. 1. Immunol Today. 1994 Jul;15(7):321-31 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal